[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorJohn O. Prior
About this trial
Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute cellular cardiac allograft rejection (ACR), cardiac sarcoidosis (CS) and the immune checkpoint inhibitor induced myocarditis (ICIM), for which non-invasive diagnosis remains challenging.
Since accurate diagnosis of myocardial inflammation in an early stage is crucial, this study aims to investigate the accuracy of \[68Ga\]Ga-PentixaFor as a marker of for the presence of inflammatory cells (T-lymphocytes and M1) in described patients.
The identification of a correlation between \[68Ga\]Ga-PentixaFor myocardial accumulation with currently accepted diagnostic tools would open up new ways to non-invasively diagnose acute myocardial inflammation.
Eligibility criteria
Qualifiers
signed written informed consent
male or female
age ≥ 18 years
patients with suspicion CS (group II) or ICIM (group III) or in their regular follow-up in their first year after HT (group I)
Disqualifiers
absence of a signed written informed consent
patients aged < 18 years
claustrophobia
myocardial ischemia in non-invasive perfusion test or coronarography in group II and III
Trial design
Treatments tested in this trial
- [68Ga]Ga-PentixaFor PET/CT
Treatment groups
69 Participants
are divided into 3 treatment groupsSponsors and collaborators
John O. Prior
Lead sponsor
University of Lausanne Hospitals
Sponsor institution
Source ClinicalTrials.gov